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Abstract
Myocardial toxicity and drug resistance caused by drug efflux are major limitations of doxorubicin 
(Dox)-based chemotherapy. Dox structure modification could be used to develop conjugates with 
an improved biological profile, such as antiproliferative activity and higher cellular retention. 
Thus, Dox thiol conjugates, Dox thiol (Dox-SH), thiol-reactive Dox-SS-pyridine (SS = disulfide), 
and a Dox-SS-cell-penetrating cyclic peptide, Dox-SS-[C(WR)4K], were synthesized. Dox was 
reacted with Trauťs reagent to generate Dox-SH. The thiol group was activated by the reaction 
with dithiodipyridine to afford the corresponding Dox-SS-Pyridine (Dox-SS-Pyr). A cyclic cell­
penetrating peptide containing a cysteine residue [C(WR)4K] was prepared using Fmoc solid­
phase strategy. Dox-SS-Py was reacted with the free sulfhydryl of cysteine in [C(WR)4K] to 
generate Dox-SS-[C(WR)4K] as a Dox-cyclic peptide conjugate. Cytotoxicity of the compounds 
was examined in human embryonic kidney (HEK-293), human ovarian cancer (SKOV-3), human 
fibrosarcoma (HT-1080), and human leukemia (CCRF-CEM) cells. Dox-SH and Dox-SS-pyridine 
were found to have significantly higher or comparable cytotoxicity when compared to Dox in 
HEK-293, HT-1080, and CCRF-CEM cells after 24 h and 72 incubation, presumably because of 
higher activity and retention of the compounds in these cells. Furthermore, Dox-SS-[C(WR)4K] 
showed significantly higher cytotoxic activity in HEK-293, HT-1080, and SKOV-3 cells when 
compared with Dox after 72 h incubation. Dox-SS-Pyr exhibited higher cellular uptake than 
Dox-SS-[C(WR)4K] in HT-1080 and HEK-293 cells as shown by flow cytometry. Fluorescence 
microscopy exhibited that Dox-SS-Pyr, Dox-SH, and Dox-SS-[C(WR)4K] localized in the 
nucleus as shown in four cell lines, HT-1080, SKOV-3, MDA-MB-468, and MCF-7. Of note, 
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Dox-SS-[C(WR)4K] was significantly less toxic in mouse myoblast cells compared to Dox at 
the same concentration. Further mechanistic study demonstrated that the level of intracellular 
reactive oxygen species (ROS) in myoblast cells exposed to Dox-SS-[C(WR)4K] was reduced 
in comparison of Dox when co-treated with FeCl2. These data indicate that Dox-SH, Dox-SS­
Pyr, and Dox-SS-[C(WR)4K] have the potential to be further examined as Dox alternatives and 
anticancer agents.
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1. Introduction
Cancer remains among the leading causes of morbidity and mortality around the world. 
Approximately 17.5 million new cases and 8.7 million cancer-related deaths were reported 
in 2015. During the next two decades, the number of new cases is estimated to rise by 
70% [1]. Consequently, there is an urgent need to synthesize new potent and less toxic 
chemotherapeutic agents.
One of the major limitations of cancer chemotherapy treatment is the development of tumor 
resistance to the conventional chemotherapy. Tumors generally develop chemoresistance to 
repeated treatment with one type of anticancer agent and then often become resistant to 
similar or completely different drugs, which is called multidrug resistance (MDR). There are 
two main classes of membrane transporter proteins which influence the pharmacokinetics 
of drugs in cells, adenosine triphosphate-binding cassette (ABC) and solute carrier (SLC) 
transporters, and their changes lead to MDR in tumors. In this regard, several hypotheses 
have been proposed to account for the phenomenon of drug resistance, including alteration 
of the target protein, decreased membrane permeability and drug metabolism, and/or efflux 
pumping [2–4].
Doxorubicin (Dox) has been one of the most effective anthracycline antibiotics with a broad 
anti-tumor spectrum since more than 50 years ago, as mono or in combination therapy 
for the treatment of a variety of tumors, including solid tumors, soft tissue sarcomas, and 
hematological malignancies [5–9]. Over the years, a variety of different mechanisms has 
been proposed for the cytostatic and cytotoxic of Dox activity. However, the mechanism 
of actions is uncertain and has long been the subject of considerable controversy [10]. The 
main mechanism is the inhibition of topoisomerase II, critical to DNA function, causing 
DNA damage by intercalation the DNA double helix [11,12]. Unfortunately, the use of Dox 
has been limited clinically, due to its pharmacokinetics properties, such as rapid distribution, 
excretion and low bioavailability, high volume of distribution, and short half-life [13–15]. 
Moreover, a high cumulative dose of Dox leads to dose-dependent side effects, such as 
cumulative cardiotoxicity, nephrotoxicity, and extravasation [16–18]. Furthermore, Dox is 
not used commonly for the treatment a number of tumors [19,20] due to efflux pumping, 
such as ovarian carcinoma cells, leading to extrusion of Dox, keeping intracellular drug 
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concentration below a cell-killing limit [21] that could be related to the overexpression of 
energy-dependent drug efflux pump protein transporter, such as P-glycoprotein (P-gp).
Carrier-mediated drug delivery has emerged as a powerful methodology for optimizing 
cellular uptake, improving the efficacy, and reducing the cytotoxicity of anticancer drugs 
[22]. In this regard, drug delivery systems are viewed as one of the main pillars to overcome 
MDR, through P-gp inhibition consequently, blocking efflux pump [23–26]. The prodrug 
strategy, in which different substances can be attached to the molecule to modify its 
chemical structure, has gained much attention in Dox delivery [27–29]. Several conjugation 
methods have been used to improve Dox delivery including polymeric nanoparticles [30], 
polymeric micelles [31], liposomes [32], lipids [33], dendrimers [34], and peptides [35–
37]. However, the release of the drug from the carrier is based primarily on reactions 
catalyzed by endogenous physiological factors such as reduction [38], low pH [39], and 
hydrolytic enzymes [40] and still presents a challenge. In this regard, researchers are 
trying to incorporate Glutathione (GSH)-responsive moieties to impart stimuli-responsive 
properties [41–43].
We have previously reported that cyclic peptides containing 4 arginine and 4 tryptophan 
residues can act as a cell-penetrating peptide and molecular transporter [44–46]. Cyclic 
[W(RW)4]-Dox conjugate containing an ester linker between the cyclic peptide-linker and 
Dox exhibited 3.6-fold higher cellular uptake when compared with Dox alone in ovarian 
cancer cells after 24 h incubation, and 99% of the conjugate was hydrolyzed to release Dox 
intracellularly after 72 h [47].
The objective of this study was to generate Dox thiol derivatives for improving the Dox 
biological profile, such as antiproliferative activity, cellular uptake, nuclear delivery, and 
retention. Herein, a cell-penetrating cyclic peptide composed of arginine (R) and tryptophan 
(W) was designed and conjugated with Dox via disulfide bridge to construct a smart drug 
delivery system Dox-SS-[C(WR)4K]. The conjugate was evaluated for the antiproliferative 
activity in different cancer cell lines, cellular uptake, and retention. We hypothesized that 
Dox conjugation through the disulfide bridge with a cell-penetrating cyclic peptide would be 
more efficient in antiproliferative activity against cancer cells that have a high concentration 
of glutathione activity compared to the normal cells [48]. The disulfide bridge is expected to 
be advantageous because they can be cleaved easily by disulfide exchange with intracellular 
thiol such as glutathione. Furthermore, we also evaluated the antiproliferative activity 
of Dox thiol derivatives, Dox-SH and Dox-SS-Pyridine (Dox-SS-Pyr), as potential Dox 
alternatives in comparison with Dox-SS-[C(WR)4K] and Dox.
2. Results and discussion
2.1. Chemistry
2.1.1. Synthesis of cyclic peptide [C(WR)4K]—Cyclic peptide was composed of 
positively-charged arginine (R) and hydrophobic tryptophan (W), in addition to β-Alanine 
(A), lysine (K) and cysteine (C) residues and was synthesized by using a solid phase 
methodology according to the previously reported procedure [49]. The thiol group in 
cysteine moiety was used for the conjugation to the thiol-containing anticancer drug. The 
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peptide sequence was designed to have lysine and β-Ala moieties as the spacer to provide a 
free NH2 group with less steric hindrance.
As shown in Scheme 1, the linear protected peptide (Fmoc-R(Pbf = 
2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl) C(Trt; trityl)R(Pbf)W(Boc = t­
butoxycarbonyl)R(Pbf)W(Boc)K(β-A(Boc))W(Boc)R(Pbf)W(Boc)) was assembled on acid­
labile chlorotrityl resin, followed by removing the last Fmoc (fluorenylmethyloxycarbonyl) 
group on the N-terminal by piperidine (20% v/v, DMF). The peptidyl-resin was washed, 
dried, and the resin was removed by a mild acidic cocktail cleavage (DCM/TFE/AcOH) [50] 
to afford the linear protected peptide with free amino and carboxylic groups. The peptide 
was cyclized using 1-hydroxy-7-azabenzotriazole (HOAt) and N,N'-diisopropylcarbodiimide 
(DIC) as coupling reagents under anhydrous conditions, followed by side chain deprotection 
to generate the targeted peptide[C(WR)4K]. The structure of the cyclic peptide was 
confirmed by MALDI-TOF/TOF mass spectrometry, showing a peak of 1675.4534 Da 
(Supporting Information), corresponding to [M+5H]+.
2.1.2. Synthesis of Dox-SH, Dox-SS-Pyr—Moreover, Dox was modified by reacting 
with a bifunctional cross linking agent. The amine group of Dox was reacted with 2­
iminothiolane hydrochloride (Trauťs reagent) under optimal conditions of basic medium to 
generate Dox-SH, containing an amidine with a free sulfhydryl group, which was activated 
by reacting with pyridyl disulfide (Pyr-SS-Pyr) (SS = disulfide) in acidic medium, affording 
the corresponding more reactive Dox-SS-Pyr containing a disulfide bridge with extrusion 
of pyridine-2-thione as depicted in Scheme 2. This type of chemical modification for Dox 
permitted the conjugation with the thiol group in the cysteine - of the cyclic peptide.
2.1.3. Synthesis of Dox-SS-[C(WR)4K]—Cyclic peptide [C(WR)4K] was conjugated 
with Dox-activated disulfide (Dox-SS-Pyr) via thiolate-disulfide interchange, using water 
as a polar protic solvent (Scheme 3). Mass spectra showed 2315.3719 Da corresponding 
to [M+2H]+, in addition to 1919.0574 (extrusion tetracyclic anthracycline aglycone) and 
1672.0049 (the cysteinyl peptide) as fragments (Supporting Information, 1D) since disulfide 
peptide can be specifically fragmented at S-S bond during MALDI-MS as shown previously 
for other disulfide compounds [51]. The Dox-SS-[C(WR)4K] product was purified by 
reverse-phase preparative HPLC (RP-HPLC) on a C18 column and lyophilized. The purity 
of the product was determined by analytical HPLC (Supporting Information, 3D).
2.2. Biological activities
Dox is commonly used in the treatment of leukemia, multiple lymphoma, thyroid, ovarian, 
lung, and breast cancers. Thus, antiproliferative activity of Dox-SH, Dox-SS-Pyr, and the 
conjugate were compared with Dox at a concentration of 5 μM in human leukemia cell line 
(CCRF-CEM, ATCC No. CCL-119) [6], human ovarian cancer cells (SKOV-3, ATCC No. 
HTB-77), human fibrosarcoma cells (HT-1080, ATCC No. CRL 12012) [7,52], and human 
embryonic kidney cells (HEK-293, ATCC No. CRL-1573) [53,54] (Figs. 1 and 2). We 
chose different cancer cell lines (e.g. CCRF-CEM, SKOV-3, HT-1080) and normal human 
embryonic kidney cells (HEK-293) to test both cytotoxicity and antiproliferative activity of 
synthesized compounds versus Dox.
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Fig. 1 shows the antiproliferative activity of Dox versus Dox-SS-Pyr and Dox-SH. Dox-SS­
Pyr inhibited the cell proliferation of HEK-293 (66%), HT-1080 (80%), and SKOV-3 (72%), 
and CCRF-CEM cells (46%) after 24 h incubation while Dox alone exhibited inhibition 
the cell proliferation of HEK-293 (57%), HT-1080 (66%), and SKOV-3 (76%), and CCRF­
CEM cells (45%). Thus, Dox-SS-Pyr showed significantly higher cytotoxicity than Dox in 
HEK-293 and HT-1080 when compared with Dox while showed comparable activity against 
and SKOV-3 cells CCRF-CEM cells after 24 h incubation.
After 72 h incubation, Dox-SS-Pyr inhibited the cell proliferation of HEK-293 (60%), 
HT-1080 (68%), and SKOV-3 (39%), and CCRF-CEM cells (73%). Dox alone did not 
exhibit inhibition the cell proliferation of HEK-293 and HT-1080, while inhibited the 
proliferation of SKOV-3 (51%) and CCRF-CEM cells (69%). Thus, Dox-SS-Pyr was more 
cytotoxic than Dox in all cell lines except SKOV-3 after 72 h incubation when compared 
with Dox. The antiproliferative activities of the compounds in HEK-293, HT-1080, and 
SKOV-3 were found to be less after 72 h, possibly due to the efflux mechanism. However, 
this effect was more obvious in HEK-293 and HT-1080 where Dox did not show any 
significant cytotoxicity. Thus, Dox-SS-Pyr enhances the intracellular retention of Dox in 
HEK-293 and HT-1080 cells while Dox had no effect.
Dox-SH inhibited the cell proliferation of HEK-293 (61% and 64%), HT-1080 (62% and 
68%), and SKOV-3 (64% and 42%), and CCRF-CEM cells (48% and 73%) after 24 h and 
72 h incubation, respectively, suggesting slightly higher inhibition and retention in all cells 
in longer incubation time except SKOV-3 cells. Furthermore, Dox-SH was found to be more 
cytotoxic in all cell lines except SKOV-3 cells when compared with Dox alone after 24 h 
and 72 h incubation. Dox-SH was less cytotoxic in HEK-293, HT-1080, and SKOV-3 cells 
when compared with Dox-SS-Pyr after 24 h incubation, but showed comparable activity 
after 72 h incubation. These data indicate Dox-SH and Dox-SS-Pyr have significantly higher 
or comparable antiproliferative activity when compared to Dox in HEK-293, HT-1080, and 
CCRF-CEM cells after 24 h and 72 incubation, presumably because of higher activity and 
retention of the compounds in these cells. We speculate Dox-SS-Pyr hydrolyzes and releases 
Dox-SH slowly in the presence of intracellular thiol groups, such as glutathione. Hence, 
Dox-SH and Dox-SS-Pyr have comparable activity after 72 h.
Fig. 2 shows the antiproliferative activity of the cyclic peptide [C(WR)4K], Dox-SS­
[C(WR)4K], and the physical mixture of Dox and [C(WR)4K] versus Dox. In general, 
cyclic peptide [C(WR)4K] alone did not exhibit any significant cytotoxicity against HT-1080 
and CCRF-CEM cells after 24 h incubation and against HEK-293 and CCRF-CEM cells 
after 72 h incubation. The compound inhibited the proliferation of HEK-293 (12%) and 
SKOV-3 cells (13%) after 24 h incubation and HT-1080 (12%) and SKOV-3 (6%) after 
72 h incubation. Thus, the contribution of the cyclic peptide in overall cytotoxicity in 
the conjugate is minimal. While Dox-SS-[C(WR)4K] exhibited slightly higher inhibition 
of proliferation in SKOV-3 cells when compared with Dox (71% versus 66%) after 24 h 
incubation, comparable cytotoxicity was observed when two compounds were compared in 
HEK-293, HT-1080, and CCRF-CEM cells. The physical mixture of Dox and [C(WR)4K] 
also exhibited comparable cytotoxicity with Dox in all cell lines after 24 h incubation.
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On the other hand, Dox-SS-[C(WR)4K] inhibited the proliferation of HEK-293 (32%), 
HT-1080 (49%), SKOV-3 (58%), and CCRF-CEM cells (68%) after 72 h incubation while 
Dox alone did not inhibit the cell proliferation of HEK-293 and HT-1080 cells and exhibited 
antiproliferative activity in SKOV-3 (51%) and CCRF-CEM cells (69%). Thus, Dox-SS­
[C(WR)4K] showed comparatively higher cytotoxicity in HEK-293, HT-1080, and SKOV-3 
cells when compared with Dox after 72 h incubation, suggesting that the conjugate enhanced 
the retention of Dox in these cells presumably by slowly releasing Dox and reducing the 
efflux.
The physical mixture of Dox and [C(WR)4K] was found to show no inhibition in HEK-293 
and HT-1080 cells after 72 h incubation similar to Dox but showed comparable activity 
with Dox in SKOV-3 and CCRF-CEM cells. These data indicate that the physical mixture 
has no advantage compared to Dox, and the cytotoxicity of the physical mixture is due to 
the presence of free Dox. Furthermore, the cyclic peptide does not improve the delivery or 
retention of Dox when used in the physical mixture form with Dox. On the other hand, 
Dox-SS-[C(WR)4K] is more cytotoxic than Dox in HEK-293, HT-1080, and SKOV-3 cells 
after 72 h incubation, suggesting the potential of the conjugate to improve the cytotoxicity 
and retention of Dox.
Comparison of Dox-SS-[C(WR)4K] with Dox-SS-Pyr (Figs. 1 and 2) revealed that the 
conjugate was significantly less cytotoxic than Dox-SS-Pyr in HEK-293 (54% versus 66%), 
HT-1080 (51% versus 80%) and showed comparable activity against SKOV-3 (71% versus 
72%), and CCRF-CEM (42% versus 46%), respectively, after 24 h incubation. Similarly the 
Dox-SS-[C(WR)4K] was less cytotoxic than Dox-SS-Pyr in HEK-293 (32% versus 60%), 
HT-1080 (49% versus 68%), and CCRF-CEM (68% versus 73%) cells after 72 h incubation, 
but was more cytotoxic against SKOV-3 (58% versus 39%), respectively. These data suggest 
that Dox-SS-Pyr has higher antiproliferative activity than the conjugate in all cell lines after 
24 h incubation and in HEK-293, HT-1080, and CCRF-CEM cells after 72 h incubation.
Flow cytometry was used to determine the cellular uptake of the conjugate Dox-SS­
[C(WR)4K] versus Dox-SS-Pyr in HEK-293, HT-1080, SKOV-3, and CCRF-CEM cells 
(Fig. 3). Cellular uptake studies indicated that Dox-SS-Pyr had higher cellular uptake in 
HT-1080, HEK-293, and CCRF-CEM cells when compared with Dox-SS-[C(WR)4K]. Dox 
and Dox-SS-[C(WR)4K] showed a similar pattern and had higher cellular uptake in SKOV-3 
and HT-1080 cells.
Based on the cytotoxicity and flow cytometry data Dox-SH, Dox-SS-Pyr, and Dox-SS­
[C(WR)4K] were selected for fluorescence microscopy studies. Fluorescence microscopy 
was used to evaluate the cellular uptake and cellular localization in HT-1080, SKOV-3, 
human breast adenocarcinoma (MDA-MB-468, ATCC No. HTB-132), and human breast 
adenocarcinoma cell (MCF-7, ATCC No. HTB-22). Figs. 4 and 5, and S1 show localization 
of all the compounds after 1 h and 24 h in the nucleus in HT-1080, MDA-MB-468, and 
MCF-7 cells. Dox-SH and Dox-SS-Pyr exhibited much higher intensity when compared 
with Dox as shown in Figs. 4 and 5, and Figures S1 and S2 (Supporting Information).
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Dox-SS-[C(WR)4K] and Dox was localized in the nucleus after 1 h and 24 h in SKOV-3 
cells while Dox-SH and Dox-SS-Pyr were distributed mostly outside the nucleus after 1 h. 
After 24 h, all the compounds were mostly localized in the nucleus (Figure S2), suggesting 
the slow nuclear localization of Dox-SH and Dox-SS-Pyr in SKOV-3 cells. These data 
indicate that Dox-SH, Dox-SS-Pyr and Dox-SS-[C(WR)4K] can be localized in the nucleus 
that allows DNA targeting by potentially released Dox or the intact compound.
2.3. Cytotoxicity in mouse myoblast cells
The clinical use of Dox is greatly limited by the risk of developing severe cardiomyopathy 
and congestive heart failure. In order to investigate the potential cardiotoxicity of Dox­
SS-[C(WR)4K] in comparison to Dox, a mouse myoblast cell line (C2C12, ATCC No. 
CRL 1772) was used in the study. Cells were maintained in DMEM (ATCC No. 30–
2002) containing 10% fetal bovine serum at 37 °C. After incubation with Dox or Dox­
SS-[C(WR)4K] for 72 h, cell viability was determined by MTT colorimetric analysis as 
described before [55].
As shown in Fig. 6, at m5M concentration, Dox treatment significantly reduced the cell 
viability to 28.6% of control, while in cells exposed to Dox-SS-[C(WR)4K], the cell 
survival rate was significantly increased (71% of control, p < 0.05 compared to Dox alone), 
indicating that Dox-SS-[C(WR)4K] may exhibit less cardiotoxicity in comparison to Dox.
Oxidative stress has been well documented as the primary cause of anthracycline­
induced cardiotoxicity (AIC) [56], which is exacerbated by iron overload [56,57]. To 
further determine the effect of Dox-SS-[C(WR)4K] on reactive oxygen spices (ROS), 
we conducted flow cytometry analysis using a cell-permeant fluorogenic reagent 2',7'­
dichlorodihydrofluorescein diacetate (H2DCFDA) (ThermoFisher Scientific, Cat. No. 
D399), which can detect intracellular reactive oxygen intermediates.
Cultured C2C12 cells in a 6 well plate were treated with Fe2+ (10 μM) in the absence or 
presence of Dox or Dox-SS-[C(WR)4K] (0.5 μM) for 72 h. Once the incubation period was 
complete, cells were collected and stained with H2DCFDA (10 μM) to detect intracellular 
ROS levels [55].
As shown in Fig. 7, FeCl2 treatment increased the intracellular ROS levels to 2.5-fold of 
control, while the levels of ROS in cells exposed to Dox or Dox-SS-[C(WR)4K] alone at low 
concentration (0.5 mM) were not elevated in comparison to that of control cells (1.09-fold 
and 1.05-fold of control respectively). Notably, the coincubation of Dox with Fe2+ increased 
ROS levels higher to 3.48-folds of control; however, induction in Fe2+-treated cells was not 
observed in the presence of Dox-SS-[C(WR)4K]. The distinct pattern of effects on ROS 
generation between Dox and Dox-SS-[C(WR)4K] may explain, at least partially, the reduced 
cytotoxicity of Dox-SS-[C(WR)4K] in C2C12 cells. Further study is warranted to define the 
underlying mechanisms.
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Dox thiol conjugates, thiolated doxorubicin (Dox-SH), thiol-reactive Dox-SS-Pyr, and a 
Dox-SS-cell-penetrating cyclic peptide, Dox-SS-[C(WR)4K] were synthesized and purified 
by using RP-HPLC. Dox-SS-Pyr showed significantly higher antiproliferative activity than 
Dox in HEK-293, HT-1080, and SKOV-3 cells when compared with Dox which showed 
comparable activity against CCRF-CEM cells after 24 h incubation. Dox-SS-[C(WR)4K] 
was found to be more cytotoxic in HEK-293, HT-1080, and SKOV-3 cells when compared 
with Dox after 72 h incubation. Dox-SS-Pyr exhibited higher cellular uptake in HT-1080, 
HEK-293, and CCRF-CEM cells as shown by flow cytometry when compared with Dox-SS­
[C(WR)4K]. Dox-SS-Pyr, Dox-SH, and Dox-SS-[C(WR)4K] showed high cellular uptake 
and were localized mostly in the nucleus as shown consistently in four different cancer 
cell lines by fluorescence microscopy studies. Our study further demonstrated that Dox-SS­
[C(WR)4K] exhibited less cytotoxicity in mouse myoblast cells in comparison to Dox. 
Intracellular ROS levels were elevated by the co-treatment of Dox and Fe2+, but such 
induction was not evident in cells exposed to Dox-SS-[C(WR)4K] and Fe2+. These data 
indicate that these compounds can be considered as Dox alternatives and anticancer agents, 
which may exhibit less cardiotoxicity in comparison to Dox.
4. Experimental section
4.1. Materials and methods
The resin, Fmoc-protected amino acid building blocks, and chemical reagents were 
purchased from AAPPTec. All solvents used for peptide synthesis or HPLC solvents 
were obtained from Sigma-Aldrich, USA and used without further purification. Peptide 
purification was carried out using Shimadzu RP-HPLC system, C18 column (19 cm × 250 
mm), and the purity was confirmed by analytical HPLC, using water (0.1% TFA) as eluent 
A and acetonitrile (0.1% TFA) as eluent B. NMR spectra were recorded on a Bruker Avance 
III HDTM 400 NMR spectrometer using DMSO-d6 as the solvent and TMS as internal 
reference. Mass spectra were obtained by a Bruker Impact 11, UHR-qTOF and a Bruker 
Daltonics Autoflex MALDI-TOF, with α-cyano-4-hydroxycinnamic Acid (CHCA) as the 
matrix (15 mg/mL).
4.2. Chemistry
4.2.1. Synthesis cyclic peptide [C(WR)4K]—Cyclic peptide [C(WR)4K] 
was synthesized by Fmoc/tBu solid-phase peptide synthesis strategy. The 
coupling and activating reagents were N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uro­
niumhexafluorophosphate (HBTU) and N,N-diisopropylethylamine (DIPEA), respectively, 
in anhydrous N,N-dimethylformamide (DMF). Fmoc was deprotected using piperidine in 
DMF (20% v/v). The H-Trp(Boc)-2-chlorotrityl resin (811 mg, 0.30 mmol, 0.37 mmol/g) 
was swelled in DMF (10 mL) for 10 min with shaking and mixing using N2. The excess 
of DMF was filtered off. The swelling and filtration steps were repeated two times before 
the coupling reactions. The solvent was drained, followed by coupling with Fmoc-Arg(Pbf)­
OH (583 mg, 0.90 mmol, 3 equiv.) using HBTU (341 mg, 0.90 mmol, 3 equiv.) and 
DIPEA (313 μL, 1.80 mmol, 6 equiv.) in anhydrous DMF (5 mL) for 1 h. The resin was 
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washed three times using DMF (3 × 10 mL), followed by deprotection of Fmoc group by 
previously prepared piperidine solution in DMF (20 mL, 20% v/v). The resin was washed 
with DMF three times (3 × 10 mL) to be ready for the next coupling. The subsequent 
amino acids, Fmoc-Trp(Boc)-OH (473 mg, 0.90 mmol, 3 equiv.), Dde-Lys(Fmoc)-OH (479 
mg, 0.90 mmol, 3 equiv.), Fmoc-Trp(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Trp(Boc)-OH, 
Fmoc-Arg(Pbf)-OH, Fmoc-Cys(Trt)-OH (527 mg, 0.90 mmol) and Fmoc-Arg(Pbf)-OH were 
coupled in the same manner. The Dde (1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl) 
group of Dde-Lys (Fmoc)-OH was removed using hydrazine hydrate in DMF (2% v/v, 20 
mL, 2 × 5 min) before coupling with Boc-β-Ala-OH (170 mg, 0.90 mmol, 3 equiv.). The 
deprotection of Fmoc groups was achieved with the piperidine solution. The side-chain 
protected peptide was cleaved from the resin by shaking the resin with a mixture of 
dichloromethane (DCM)/2,2,2-trifluoroethanol (TFE)/acetic acid (AcOH) (50 mL, 7:2:1, 
v/v/v) for 1 h. The resin was filtered off, and the solution was evaporated under vacuum, 
using hexane to remove acetic acid azeotropically. The residue was dried overnight under 
vacuum. The crude linear protected peptide was used directly for cyclization. The crude 
peptide was dissolved in a diluted solution of DMF/DCM (240 mL, 4:1 v/v) under inert gas, 
using HOAt (122 mg, 0.90 mmol) and DIC (139 μl, 0.90 mmol) as coupling reagents. 
The mixture was stirred overnight at rt. After cyclization, the solvent was evaporated 
and cleavage of the side-chain protecting groups was carried out by using trifluoroacetic 
acid (TFA)/thioanisole/1,2-ethanedithiol (EDT)/anisole (90:5:3:2, v/v/v/v, 10 mL) for 2 h. 
The crude deprotected cyclic peptide was precipitated with addition of cold diethyl ether 
treatment followed by centrifugation, providing the targeted cyclic peptide, which was 
purified by using RP-HPLC (reversed-phase high-performance liquid chromatography). The 
fraction was evaporated and lyophilized to afford the powdered cyclic peptide. MALDI-TOF 
(m/z) [C80H110N28O11S]: calcd, 1670.8630; found, 1675.4534 [M + 5H]+.
4.2.2. Synthesis thiolated doxorubicin (Dox-SH)—Dox (50 mg, 0.09 mmol) and 
2-iminothiolane hydrochloride (12 mg, 0.09 mmol) were dissolved in methanol (40 mL) 
followed by addition of a catalytic amount of triethylamine (TEA) and stirred at rt for 7 h. 
After evaporation of the solution, the crude product was washed multiple times with diethyl 
ether affording 45 mg (70%) of Dox-SH. 1H NMR (DMSO-d6 + D2O, 400 MHz, δ ppm): 
7.90–7.83 (m, 2H, ArC1H, ArC2H), 7.62–7.60 (m, 1H, ArC3H), 5.26 (t, J = 12.0 Hz, 1H, 
H-1'), 4.95–4.86 (m, 1H, H-14), 4.50–4.59 (m, 3H, H-14 and H-7), 4.15 (d, J = 8.0 Hz, 
1H, H-50), 3.95 (d, J = 12.0 Hz, 3H, OCH3), 3.55–3.50 (m, 1H, H-4'), 3.39–3.30 (m, 1H, 
H-3'), 2.80–2.96 (m, 2H, H-10), 244–2.32 (m, 2H, CH2SH), 2.17–1.42 (m, 8H, CH2 (H-8), 
HSCH2CH2, CH2C=NH, CH2 (H-2'), 1.16–1.10 (br S, 3H, CH3); 13CNMR (DMSO-d6 + 
D2O, 100 MHz, δ ppm): 214.39 (C13 = O), 187.07 (C12 = O),186.52 (C5=O), 166.53 
(C-4), 161.33 (C=NH), 156.16 (C-6), 154..62 (C-11), 137.13 (C-6a), 135.40 (C-10a), 135.06 
(C-12a), 134.51 (C-2), 120.33 (C-4a), 120.23 (C-1), 119.76 (C-3), 111.30 (C-5a), 110.93 
(C-11a), 99.81 (C-1'), 75.73 (C-9), 75.37 (C-7), 70.35 (C-4'), 66.75 (C-5'), 64.25 (C-14), 
57.16 (C4-OCH3), 47.06 (C3'), 36.77 (C-8), 32.57 (C-10), 32.46 (C-2'), 28.56 (CH2C(NH) 
= NH), 27.53 (CH2SH), 26.82 (CH2CH2SH), 17.21 (C-5'-CH3); HR-MS (ESI-qTOF) (m/z) 
[C31H36N2O11S]: calcd, 644.2040; found 645.4678 [M+H]+.
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4.2.3. Synthesis of pyridyl doxorubicin (Dox-SS-Pyr)—Thiolated Dox (100 mg, 
0.15 mmol) and 2,2'-dithiodipyridine (33 mg, 0.15 mmol) were dissolved in methanol 
(40 mL) followed by adding a catalytic amount of acetic acid (AcOH). The mixture was 
stirred overnight at room temperature. After evaporation of the solution, the precipitated 
product was crystallized from diethyl ether, affording 85 mg (73%) of Dox-SS-Pyr. 1H NMR 
(DMSO-d6, 400 MHz, δ ppm): 14.08 (s, 1H, OH Phenolic C-6), 13.28 (s, 1H, OH Phenolic 
C-11), 8.47–7.28 (m, 9H, NH and ArH), 5.37–5.31 (m, 2H, CH2OH), 5.04–5.01 (m, 2H, 
OH Sugar and OH cyclohexane), 4.61–4.55 (m, 1H, OH, CH2OH), 3.98 (s, 3H, OCH3), 
1.61–1.57 (m, 17H, CH2 and CH of sugar, cyclohexane and thiolane), 1.14 (d, J = 6.8 
Hz, 3H, CH3); 13C NMR (DMSO-d6, 100 MHz, δ ppm): 207.80 (C13 = O),186.90 (C12 = 
O), 185.70 (C5=O), 165.09 (C-4), 161.09 (C=NH), 158.90, 157.33, 154.39, 149.72, 149.61, 
138.17, 137.82, 136.38, 134.20, 121.82, 121.21, 119.55, 119.28, 112.83, 110.63, 110.43 (16 
Aromatic carbons), 99.26, 74.87, 68.93, 64.30, 63.06, 48.66, 38.88, 36.60, 32.56, 31.29, 
28.20, 26.43 (12C, CH2 and CH of sugar, cyclohexane and thiolane), 63.06 (CH2OH), 56.60 
(OCH3), 16.89 (CH3); HR-MS (ESI-qTOF) (m/z) [C36H39N3O11S2]: calcd, 753.2026; found 
754.4053 [M+H]+.
4.2.4. Synthesis of cyclic peptide attached doxorubicin (Dox-SS[C(WR)4K])—
A cyclic peptide ([C(WR)4K], 30 mg, 0.01 mmol) and the activated Dox (Dox-SS-Pyr, 11 
mg, 0.01 mmol) were dissolved in methanol/water mixture (1:4, v/v, 4 mL). The reaction 
mixture was stirred under nitrogen overnight at rt. After completion of the reaction as 
monitored by MALDI mass, the solution was concentrated using rotatory evaporator and 
subjected to RP-HPLC for purification, followed by analytical HPLC to confirm the purity. 
MALDI-TOF (m/z) [C111H144N30O22S2]: calcd, 2313.0513; found 2315.3719 [M + 2H]+.
4.3. Cell culture
Human embryonic kidney cells (HEK-293, ATCC No. CRL-1573), human ovarian cancer 
cells (SKOV-3, ATCC No. HTB-77), human fibrosarcoma cells (HT-1080, ATCC No. 
CRL-12012), human leukemia cell line (CCRF-CEM, ATCC No. CCL-119), human breast 
adenocarcinoma (MDA-MB-468, ATCC No. HTB-132), human breast adenocarcinoma cell 
(MCF-7, ATCC No. HTB-22), and mouse myoblast cells (C2C12, ATCC No. CRL-1772) 
were purchased from American Type Culture Collection. The cells were grown on 75 cm2 
cell culture flasks with RPMI-16 medium for CCRF. DMEM for MDA-MB-468, MCF-7, 
and C2C12, and EMEM for SKOV-3, HT-1080, and HEK-293, supplemented with 10% fetal 
bovine serum (FBS), and 1% penicillin-streptomycin solution (10,000 units of penicillin and 
10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 
°C.
4.4. Viability assay
HEK-293 (5000 cells), SKOV-3 (5000 cells), HT-1080 (5000 cells), CCRF-CEM cells 
(50,000 cells), and C2C12 (10,000 cells) were seeded in 0.1 mL per well in 96-well plates 
24 h prior to the experiment. Cells were treated with 5 μM of Dox, Dox-SH, Dox-SS-Pyr, or 
Dox-SS-[C(WR)4K]. Water and DMSO (0.025%) were used as negative control. Plates were 
incubated for 24 or 72 h at 37 °C in a humidified atmosphere of 5% CO2. Before adding 
MTT or MTS reagent, the medium of SKOV-3, HT-1080, and HEK-293 was replaced with 
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fresh medium. Cell viability was then determined by measuring the fluorescence intensity 
of the formazan product at 595 nm (MTT) or 490 nm (MTS) using a SpectraMax M2 
microplate spectrophotometer. The percentage of cell survival was calculated as [(OD value 
of cells treated with compounds) – (OD value of culture medium)]/[(OD value of control 
cells) – (OD value of culture medium)] × 100.
4.4.1. Flow cytometry—HEK-293, SKOV-3, HT-1080, and CCRF-CEM cells were 
taken in 6-well plates, 5 × 104 cells/well for adherent cells and 5 × 105 for CCRF-CEM 
as non-adherent cells in serum-free medium and incubated overnight. The next day, Dox (5 
μM), Dox-SS-Pyr (50 μM), or and Dox-SS-[C(WR)4K] (50 μM) were added to the wells. 
The cells with no treatment were used as control groups. The plates were incubated for 3 
h at 37 °C. After 3 h incubation at 37 °C, the medium containing the drugs treated with 
HEK-293, SKOV-3, and HT-1080 cells was removed, and the cells were washed once with 
Dulbecco's phosphate-buffered saline (DPBS). Then cells were detached with 0.25% trypsin/
EDTA (0.53 mM) for 5 min, neutralized with serum free fresh medium, and centrifuged at 
800 rpm for 5 min to remove any artificial surface association and to detect only intracellular 
uptake. For CCRF-CEM cells, the cells were collected after 3 h and centrifuged at 800 rpm 
for 5 min. To wash the cells, the pellets of all cell lines were resuspended in DPBS and 
centrifuged twice. Finally, the cells were resuspended in flow cytometry buffer and analyzed 
by flow cytometry (FACSCalibur: BD) using TEXAS RED channel and CellQuest software 
(BD FACSVerse). The data presented were based on the mean fluorescence signal for 10,000 
cells collected. All assays were performed in triplicate.
4.4.2. Detection of intracellular reactive oxygen species (ROS)—C2C12 cells 
were seeded in 6-well plates in DMEM medium supplemented with 10% FBS and incubated 
with 0.5% CO2 at 37 °C for 24 h prior to treatments. Cells were then incubated with 10 
μM Fe2+ with or without 0.5 νM of Dox or Dox-SS-[C(WR)4K] in serum-free DMEM for 
72 h. After treatments, cells were collected and stained with H2DCFDA (10 μM) in Hank's 
Balanced Salt Solution (HBSS) for 30 min at 37 °C followed by flow cytometry analysis. 
The mean fluorescence signal for 5000 cells is represented here as the fold of control. Each 
experiment was repeated twice.
4.5. Fluorescence microscopy
SKOV-3, HT-1080, MDA-MB-468, and MCF-7 cells were seeded on each chamber of the 
μ-Slide VI0.4 plates (ibidi cat. # 80604). 1 × 104 cells in 30 μL medium were injected to 
each chamber and incubated for 60 min to fix the cells. After this time, 60 μL of supplied 
medium was added to each column and incubated overnight in humidified atmosphere of 
95% air, 0.5% CO2 at 37 °C. The next day, the medium was removed and a solution of 
120 mL of fresh supplied medium contain final concentration of 5 mM of Dox, Dox-SH, 
Dox-SS-Pyr, or Dox-SS-[C(WR)4K] were added to each chamber and incubated for 1 and 
24 h. Cells without treatment were considered as the control group. After each treatment 
time, the medium was removed, and chambers were washed 2 times with 100 μL DPBS, 
fixed with 100 μL of 4% PFA (paraformaldehyde) for 30 min and washed again with DPBS 
for 2–3 times. Since Dox is fluorescent, no dye was added. To identify nucleus, the cells 
were dyed with 50 μL DAPI (300 nM) for 5–10 min and washed with DPBS 2 times. 
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One drop of mounting solution was added to each chamber. Plates were kept in the dark 
by rolling in aluminum foil and kept at room temperature for further analysis by Keyence 
Fluorescent microscope.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Inhibition of cells by Dox-SH (5 μM), Dox-SS-Pyr (5 μM), and Dox (5 μM) after 24 h and 
72 h incubation. The results are shown as the percentage of the control cells that have no 
compound (set at 100%). All the experiments were performed in triplicate (±SD).
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Inhibition of cells by Dox-SS-[C(WR)4K] (5 μM), a physical mixture of Dox, and 
[C(WR)4K] (1:1 ratio based on M.W., and Dox (5 μM) after 24 h and 72 h incubation. 
The results are shown as the percentage of the control cells that have no compound (set at 
100%). All the experiments were performed in triplicate (±SD).
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Flow cytometry analysis (FACS) analysis of cellular uptake assays of Dox (5 μM), Dox­
SS-Pyr (50 μM) and Dox-SS-[C(WR)4K] (50 μM) in HT-1080, HEK-293, SKOV-3, and 
CCRF-CEM cells after 3 h of incubation (mean ± SD).
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Fluorescence microscopy images of Dox (5 μM), Dox-SH (5 μM), Dox-SS-Pyr (5 μM), and 
Dox-SS-[C(WR)4K] (5 μM) uptake in HT-1080 cells after 1 h and 24 h. Cells treated with 
the compound for 1 h or 24 h. Red represents the fluorescence of Dox. To identify the 
nucleus, the cells were dyed with DAPI.
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Fluorescence microscopy images of Dox (5 μM), Dox-SH (5 μM), Dox-SS-Pyr (5 μM), and 
Dox-SS-[C(WR)4K] (5 μM) uptake in MDA-MB-468 cells after 1 h and 24 h. Cells treated 
with the compound for 1 h or 24 h. Red represents the fluorescence of Dox. To identify the 
nucleus, the cells were dyed with DAPI.
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Dox-SS-[C(WR)4K] in mouse myoblast cells after 72 h incubation compared to that of Dox. 
The results are shown as the folds of the control cells that have no compound (set at 100%). 
All the experiments were performed in triplicate (mean ± SD). *, p < 0.05 compared to 
doxorubicin.
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Flow cytometry analysis (FACS) of intracellular ROS levels using H2DCFDA staining in 
C2C12 cells. Cells were treated with Fe2+ (10 μM) in the absence or presence of Dox or 
Dox-SS-[C(WR)4K] (0.5 μM) for 72 h before staining with H2DCFDA (10 μM). Data is 
represented as the fold of control and each experiment was repeated two times.
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Synthesis of Cyclic Peptide [C(WR)4K].
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Synthesis of Dox-SH and Dox-SS-Pyr.
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